Tags

Type your tag names separated by a space and hit enter

The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy.
Aliment Pharmacol Ther. 2006 Oct 01; 24(7):1017-27.AP

Abstract

BACKGROUND

Tegaserod is a partial 5-hydroxytryptamine 4 receptor agonist with prokinetic effects on the gastrointestinal tract, its effects on oesophageal function are unknown.

AIM

A randomized, placebo controlled, double-blind trial assessed the effect of tegaserod on the oesophagus in healthy, asymptomatic subjects.

METHOD

A 7-day course of tegaserod 6 mg b.d. vs. placebo was prescribed (n = 17/21 completed both phases of study). High-resolution manometry and pH measurements were performed before and after a test meal. Bolus transport of liquids and solids was studied by high-resolution manometry and videofluoroscopy.

RESULTS

Tegaserod had no effect on lower oesophageal sphincter pressure compared with placebo, peristaltic velocity increased (P < 0.001) and distal contractile pressure decreased slightly (P < 0.05). Transient lower oesophageal sphincter relaxations and reflux were infrequent regardless of treatment. During the studies of bolus transport, high-resolution manometry revealed that tegaserod promoted mid-oesophageal contractility (P < 0.02) and shortened the 'proximal transition zone' (P < 0.05), the level where bolus escape occurred most frequently. These effects had no effect on liquid bolus transport; however a non-significant trend to improved solid bolus transport was observed (66% vs. 31%;P = 0.07).

CONCLUSION

Tegaserod did not alter lower oesophageal sphincter pressure, but had significant effects on peristaltic function. High-resolution manometry promoted mid-oesophageal contractility during bolus transport. This effect was associated with a non-significant trend to improved solid bolus transit.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, University Hospital of Zürich, Rämistrasse, Zürich, Switzerland. markfox_2@hotmail.co.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16984495

Citation

Fox, M, et al. "The Effects of Tegaserod On Oesophageal Function and Bolus Transport in Healthy Volunteers: Studies Using Concurrent High-resolution Manometry and Videofluoroscopy." Alimentary Pharmacology & Therapeutics, vol. 24, no. 7, 2006, pp. 1017-27.
Fox M, Menne D, Stutz B, et al. The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther. 2006;24(7):1017-27.
Fox, M., Menne, D., Stutz, B., Fried, M., & Schwizer, W. (2006). The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Alimentary Pharmacology & Therapeutics, 24(7), 1017-27.
Fox M, et al. The Effects of Tegaserod On Oesophageal Function and Bolus Transport in Healthy Volunteers: Studies Using Concurrent High-resolution Manometry and Videofluoroscopy. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1017-27. PubMed PMID: 16984495.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. AU - Fox,M, AU - Menne,D, AU - Stutz,B, AU - Fried,M, AU - Schwizer,W, PY - 2006/9/21/pubmed PY - 2007/5/22/medline PY - 2006/9/21/entrez SP - 1017 EP - 27 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 24 IS - 7 N2 - BACKGROUND: Tegaserod is a partial 5-hydroxytryptamine 4 receptor agonist with prokinetic effects on the gastrointestinal tract, its effects on oesophageal function are unknown. AIM: A randomized, placebo controlled, double-blind trial assessed the effect of tegaserod on the oesophagus in healthy, asymptomatic subjects. METHOD: A 7-day course of tegaserod 6 mg b.d. vs. placebo was prescribed (n = 17/21 completed both phases of study). High-resolution manometry and pH measurements were performed before and after a test meal. Bolus transport of liquids and solids was studied by high-resolution manometry and videofluoroscopy. RESULTS: Tegaserod had no effect on lower oesophageal sphincter pressure compared with placebo, peristaltic velocity increased (P < 0.001) and distal contractile pressure decreased slightly (P < 0.05). Transient lower oesophageal sphincter relaxations and reflux were infrequent regardless of treatment. During the studies of bolus transport, high-resolution manometry revealed that tegaserod promoted mid-oesophageal contractility (P < 0.02) and shortened the 'proximal transition zone' (P < 0.05), the level where bolus escape occurred most frequently. These effects had no effect on liquid bolus transport; however a non-significant trend to improved solid bolus transport was observed (66% vs. 31%;P = 0.07). CONCLUSION: Tegaserod did not alter lower oesophageal sphincter pressure, but had significant effects on peristaltic function. High-resolution manometry promoted mid-oesophageal contractility during bolus transport. This effect was associated with a non-significant trend to improved solid bolus transit. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16984495/The_effects_of_tegaserod_on_oesophageal_function_and_bolus_transport_in_healthy_volunteers:_studies_using_concurrent_high_resolution_manometry_and_videofluoroscopy_ L2 - https://doi.org/10.1111/j.1365-2036.2006.03090.x DB - PRIME DP - Unbound Medicine ER -